Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

This is the first trial combining Allarity’s stenoparib with another anti-cancer agentStenoparib’s favorable safety profile supports ...

This is a "landmark study" for cancer immunotherapy and circadian medicine, researcher say ...

University of Queensland researchers who mapped cancer cell "neighborhoods" in the most common type of lung cancer have found ...

Key opportunities in the Global Small Cell Lung Cancer Therapeutics Market include the growing demand for advanced ...

An international team confirms in a pioneering phase 3 clinical trial the decisive role of the time of day on the success of anti-tumour immunotherapies. Huang, Z., Zeng, L., Ruan, Z. et al.

Study Highlights the Efficacy of PMC in Suppressing Non-Small Cell Lung Cancer Growth SEOUL, SOUTH KOREA, January 23, 2026 /EINPresswire.com/ — A South Korean research team has found that ...

Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...